TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female and/or male inpatients or outpatients, aged over 18 years and under 65 years~* Documented clinical diagnosis meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria~* YMRS total score =20 at enrollment and randomization (Day 1) Patients had a history of at least one manic episode that required hospitalization and/or treatment with a mood stabilizer or antipsychotic.~* Female patients must have a negative urine human chorionic gonadotropin (HCG) test at enrolment and must be using a reliable method of birth control, ie, barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive~Exclusion Criteria:~* Pregnancy or lactation Meeting the criteria for any other (than bipolar disorder) DSM-IV Axis I diagnosis, concomitant organic mental disorder or mental retardation~* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others~* Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomization/baseline~* Known intolerance or hypersensitivity to, or lack of response to previous treatment with quetiapine fumarate or lithium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Seroquel XR tablet
- 2 (Type: ACTIVE_COMPARATOR): Seroquel XR + lithium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy-proven within 3ws~2. Primary IgAN or Henoch-Schönlein Purpura nephritis of crescent \>50%(\>8 glomeruli)~3. Serum creatinine ≥ 200 μmol/l， rapidly deterioration of renal function~Exclusion Criteria:~1. \<14 or \>65 years old~2. With high Scr requiring dialysis for≥ 3w~3. Scr\>200μmol/L ≥1 yr before entry~4. Main of old crescent ; Fibrous crescent\>50%~5. Anti-glomerular basement membrane (GBM) or antineutrophil cytoplasmic antibody (ANCA) antibody positive~6. Women in gestational and lactational period~7. With diabetes or uncontrollable malignant hypertension or Thrombotic Microangiopathy~8. With Malignancy~9. Chronic active infection including HBV hepatitis C virus (HCV) HIV or active tuberculosis~10. Other autoimmune disease~11. A second clearly defined cause of renal failure~12. Contraindication of plasma exchange treatment or steroid pulse~13. Patients who are unlikely to comply with the study protocol in the view of the treating physician.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PE and methylprednisolone pulse (Type: EXPERIMENTAL): Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange \>7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
- Methylprednisolone pulse (Type: ACTIVE_COMPARATOR): Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma vs. Standard Plasma for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
There are 2 groups of research subjects: plasma donor and recipients~Volunteer plasma donors can donate Convalescent Plasma if they:~* have adequate antibody levels against COVID-19 per FDA Guidelines~* have had no symptoms of COVID-19 for at least 14 days~* meet routine plasma donation criteria~Inclusion Criteria for Plasma Recipients:~* Adults 18 years of age or older~* Hospitalized with PCR+ COVID-19 infection~* If female must not be pregnant and/or breastfeeding.~Exclusion Criteria for Plasma Recipients:~* Unable to randomize patient within 14 days of admission to Stony Brook Hospital (or any other hospital if a transfer to Stony Brook Hospital).~* In the treating physician's opinion, the patient cannot tolerate a 450-550 mL infusion of plasma over up to 8 hours (4 hours max per unit), even if prophylaxed with intravenous diuretic~* Contraindication to transfusion or history of prior reactions to blood transfusions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Donor Plasma (Type: ACTIVE_COMPARATOR): None
- Standard Donor Plasma (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Future Mental Projections in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* for patients only~* male or female~* age limits : 18-55 years old~* under the protection of health insurance~* who have signed up the consent form~* schizophrenia or schizo-affective disorder according to the DSM-5 criteria (APA, 2013).~* clinically stable for at least 2 months~* patients under guardianship or curatorship need agreement of their legal representative~* informed of the results of prior medical examination for controls only~* male or female~* age limits : 18-55 years old~* under the protection of health insurance~* who have sign up the consent form~* recruited from the general population and matched on gender, age years of schooling~* no psychiatric history (DSM-5)~Exclusion Criteria:~* for both patients and controls~* current severe or unstable somatic illness~* neurological history (brain injury \> 15 minutes loss of consciousness , epilepsia, brain surgery...)~* current substance use disorder (DSM-5)~* current major depressive disorder (CDSS,BDI, HDRS)~* mental retardation (IQ \< 70, WAIS-4, f-NART)~* history of general anesthesia 3 months prior to the experiment~* pregnancy declared by the subject~* breast feeding~* current legal control~* in emergency situation~* included during exclusion period in another experiment~* for controls only~* taking of antipsychotic drugs for the 3 weeks prior to inclusion~* under guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Patients with schizophrenia (Type: None): Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
- Control participants (Type: None): - Control participants without psychiatric nor neurological history

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinical~* Patients (men or women) at least 18 years of age and~* Presenting with ischemic chest discomfort \>20 minutes and \<6 hours of duration suggestive of acute myocardial infarction~AND:~ECG~* ST elevation \>1mm (\>0.1mV) in two contiguous limb leads OR \>2mm (\>0.2mV) in two contiguous precordial leads~Exclusion Criteria:~CLINICAL~* Maximal systolic blood pressure \<80 mmHg AFTER initial fluid and/or pressor resuscitation~* Uncontrolled hypertension (SBP\>180 OR DBP \>110) at time of enrollment~* Ventricular fibrillation or ventricular tachycardia requiring DC cardioversion~* Sinus bradycardia (HR \<50/min), third degree or advanced second degree heart block.~* Known pregnancy~* New or suspected new left bundle branch block~BIOCHEMICAL~* Known thrombocytopenia (platelet count \<100,000)~* Known severe renal insufficiency (creatinine \>4.0 mg/dL)~INCREASED BLEEDING RISK~* Active or recent (\<1 year) bleeding or gastrointestinal hemorrhage~* Major surgery \<1 month~* Known coagulopathy, platelet disorder or history of thrombocytopenia: If a patient is known to be on chronic warfarin therapy, the International Normalized Ratio (INR) must be known to be \<1.6 in order for the patient to be included~* Known neoplasm~* Any history of hemorrhagic cerebrovascular disorder or active intracranial pathology~MEDICATIONS~* Administration of a fibrinolytic agent within 7 days~* Known allergy or contraindication to eptifibatide OR aspirin OR heparin~* Treatment with another GP IIb/IIIa inhibitor within 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intracoronary injection of eptifibatide
- 2 (Type: PLACEBO_COMPARATOR): Intra-coronary injection of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Left ventricular ejection fraction 35% assessed by echocardiography, nuclear scan or left ventriculogram within the past 2 years~* Stable (NYHA) class II and III symptoms as defined by:~  1. no change in NYHA symptoms over the past 3 months;~ 2. on stable doses of ACE inhibitor and beta blocker for one month;~ 3. no episode of decompensated CHF over the past 3 months.~* Calculated creatinine clearance of equal or less than 60 ml/min and greater than 30 ml/min, using the Cockcroft-Gault formula assessed within the past 12 months~Exclusion Criteria:~* Nitrates or alpha blockers~* Prior diagnosis of intrinsic renal diseases including renal artery stenosis of \> 50%~* Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period~* Hospitalization for decompensated CHF during the past 3 months~* Myocardial infarction within 3 months of screening~* Unstable angina within 3 months of screening or any evidence of myocardial ischemia~* Significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis~* Severe congenital heart diseases~* Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening~* Second or third degree heart block without a permanent cardiac pacemaker~* Stroke within 3 months of screening or other evidence of significantly compromised CNS perfusion~* Serum sodium of \< 125 mEq/dL or \> 150 mEq/dL~* Serum potassium of \< 3.5 mEq/dL or \> 5.7 mEq/dL~* Hemoglobin \< 10 gm/dl~* Other acute or chronic medical conditions or laboratory abnormality which may increase the risks associated with study participation or may interfere with interpretation of the data~* Received an investigational drug within 1 month prior to dosing~* Patients with an allergy to iodine.~* Female subject who is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1: low dose BNP alone (Type: PLACEBO_COMPARATOR): low dose BNP with placebo
- 2: low dose BNP + PDEVI (Type: ACTIVE_COMPARATOR): low dose BNpo + PDEVI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in Protocol FB401-01, completed through Week 20 visit and able to directly enroll into this (FB401-02) study~* Refrain from use of all other atopic dermatitis treatments, unless given permission by medical monitor~Exclusion Criteria:~* Subject experienced a serious adverse event or severe adverse event attributable to study drug in Protocol FB401-01~* Severe concomitant illness that, in the Investigator's opinion, would adversely affect subject participation in the study, whether medical or psychological~* Pregnant (or planning to become pregnant during the period of the study) or lactating females

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FB-401 (Type: EXPERIMENTAL): FB-401 applied topically

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* All patients who, after IVF-PGT-A treatment with their own oocytes, present a euploid embryo for transfer.~* Transfer of a single euploid embryo~Exclusion criteria:~* Moderate or high smoking (\> 5 cigarettes/day)~* BMI ≥30 kg/m2~* Chronic hypertension~* History of preeclampsia in previous pregnancies~* History of delayed uterine growth and placental insufficiency in previous pregnancies~* Use of donor sperm~* Woman's age ≥44 years~* Women with menstrual cycles longer than 35 days

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- FROZEN EMBRYO TRANSFER IN NATURAL CYCLE (Type: NO_INTERVENTION): After confirming ovarian rest (follicles \< 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
- FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE (Type: ACTIVE_COMPARATOR): After confirming ovarian rest (follicles \< 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol \>100 pg/ml and serum progesterone \< 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lyra Gait Training on the Mobility of Geriatric Rehabilitation Inpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 65 years of age or older~* Rehabilitation inpatients at Felix Platter Hospital with primarily muscle weakness and difficulty walking~* Community-dwellers before hospital admission with planned discharge home~* Body weight 150 kg or less~* Body height between 100 cm and 195 cm~* Mini-Mental State Examination score 21 points or more~* Signed informed consent for study participation~Exclusion Criteria:~* Clinically significant neurologic or musculoskeletal diseases which severly affect walking, e.g. advanced Parkinson's disease or hemiplegia~* Severe cardiac insufficiency~* Advanced chronic pulmonary disease (COPD Gold IV)~* Amputations of extremities (except missing fingers)~* Blindness~* Inability to understand and speak German well enough to understand the patient information, training and assessment instructions

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
- Control Group (Type: ACTIVE_COMPARATOR): Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Analgesic Techniques on Duration of Spontaneously Laboring Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous,~* American Society of Anesthesia Physical Status (ASA) 2 females~* \>18 years-old~* term (\>37 weeks gestation)~* singleton~* vertex pregnancies~* spontaneous labor or spontaneous rupture of membranes~Exclusion Criteria:~* Non-vertex presentation~* induction of labor~* contraindication to opioid or neuraxial analgesia~* contraindication to combine spinal-epidural technique (e.g. unfavorable airway exam)~* cervical dilation \> 4.0 cm~* administration of systemic hydromorphone within 4 hours of epidural request

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group E (Type: ACTIVE_COMPARATOR): Epidural de novo technique
- Group BF (Type: ACTIVE_COMPARATOR): Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
- Group F (Type: ACTIVE_COMPARATOR): Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues